Investors/Partners
“Powering the next era of cancer therapy through Actinium-225 and advanced medical radioisotopes.”
Our Partners
Major Partner
TRIUMF is Canada’s national laboratory for particle and nuclear physics, located in Vancouver, and one of the world’s leading centres for accelerator science and radioisotope research. The laboratory operates advanced cyclotron and accelerator facilities that support fundamental physics, materials science, and cutting-edge nuclear medicine development.
TRIUMF is internationally recognised for its expertise in isotope production, target technology, radiochemistry, and medical isotope innovation.
Southern Cross Medical Radioisotopes (SCMR) is partnering with TRIUMF in both radioisotope separation technology and the production of medical radioisotopes.
This collaboration brings together TRIUMF’s world-class accelerator and radiochemical expertise with SCMR’s innovative separation methods and production strategies, strengthening the pathway toward reliable, scalable supplies of critical isotopes for nuclear medicine.
BOSS ENERGY is an Australian uranium company advancing domestic uranium production, best known for the Honeymoon Uranium Project in South Australia. The project utilises in-situ recovery (ISR), a modern, environmentally controlled uranium extraction method that forms part of the global nuclear materials supply chain supporting energy, research, and medical applications.
Southern Cross Medical Radioisotopes (SCMR) is working with BOSS ENERGY in relation to nuclear materials relevant to advanced medical isotope development. As part of SCMR’s radium separation program, pitchblende-derived uranium materials associated with the Honeymoon resource could be used as a source stream for radium recovery, which in turn enables the production of actinium-based medical isotopes for Targeted Alpha Therapy.
This collaboration links upstream nuclear resource expertise with downstream radiochemical processing and medical isotope production, strengthening Australia’s capability across the full nuclear medicine supply pathway, from raw material through to life-saving therapeutic isotopes.
The University of Wollongong (UOW) is a leading Australian research university recognised internationally for its strengths in science, engineering, and advanced materials. UOW hosts modern research infrastructure and interdisciplinary expertise spanning physics, chemistry, engineering, and biomedical sciences, creating an ideal environment for applied nuclear science and medical technology development.
Southern Cross Medical Radioisotopes (SCMR) is based at UOW, where core research and development activities in radioisotope separation, radiochemistry, and medical isotope production technologies are undertaken.
The partnership provides access to laboratory facilities, academic collaboration, and a multidisciplinary research ecosystem that supports SCMR’s mission to develop scalable, high-purity radioisotope production capability for nuclear medicine.
Tellus Holdings is an Australian company specialising in the safe management, treatment, and disposal of hazardous and radioactive waste. Its flagship Sandy Ridge Facility in Western Australia is designed as an engineered, secure, long-term isolation site for materials that require controlled storage and disposal.
Tellus provides critical infrastructure that supports industry, research, and medical sectors that handle regulated materials.
Southern Cross Medical Radioisotopes (SCMR) is engaging with Tellus as part of responsible lifecycle planning for medical radioisotope production and radiochemical processing activities.
This relationship supports best-practice approaches to handling, storage, and long-term management of regulated materials associated with isotope production, ensuring SCMR’s operations align with stringent safety, environmental, and regulatory standards while enabling the growth of Australia’s nuclear medicine capability.
Nuclear Australia is an Australian industry and professional organisation that supports the advancement of nuclear science, technology, and applications across energy, medicine, research, and industry.
It plays an important role in connecting government, researchers, engineers, and commercial organisations involved in nuclear-related fields, helping to strengthen national capability, collaboration, and technical expertise.
Southern Cross Medical Radioisotopes (SCMR) is working with Nuclear Australia as part of the broader effort to build Australia’s sovereign capability in medical radioisotope production and radiochemical processing.
This relationship supports knowledge exchange, industry engagement, and the development of advanced radioisotope separation and production technologies, helping position Australia as a growing contributor to global nuclear medicine supply chains.
Sydney Adventist Hospital (SAN) is one of Australia’s largest private hospitals, located in Wahroonga, Sydney. It is widely recognised for excellence in clinical care, advanced medical imaging, oncology services, and specialist treatment programs.
The hospital combines modern medical infrastructure with strong clinical research engagement, supporting the translation of new technologies into patient care.
Southern Cross Medical Radioisotopes (SCMR) is working with SAN to support the clinical and translational aspects of medical radioisotope applications.
This relationship links SCMR’s radioisotope production and radiochemical expertise with frontline medical practice, helping bridge the pathway from isotope development to real-world diagnostic and therapeutic use in nuclear medicine.
Global Medical Solutions (GMS) is an international medical technology company supporting advanced healthcare solutions across diagnostics, therapeutics, and clinical implementation. GMS has experience in translating complex technical capabilities into operational medical environments, with a strong focus on reliability, quality, and regulatory-aligned delivery.
Southern Cross Medical Radioisotopes (SCMR) is partnering with GMS as both a technical collaborator and supplier of specialised nuclear and medical equipment.
GMS will support SCMR’s activities through the provision of selected nuclear, radiochemical, and medical systems, alongside expertise that helps integrate equipment into compliant research, production, and clinical workflows.
This collaboration strengthens the end-to-end pathway from radioisotope production and separation through to clinical-ready deployment, helping ensure SCMR’s programs are supported by fit-for-purpose equipment and aligned with real-world nuclear medicine requirements.